Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 28:10:839278.
doi: 10.3389/fped.2022.839278. eCollection 2022.

Patients' Perception of the Use of the EasyPod™ Growth Hormone Injector Device and Impact on Injection Adherence: A Multi-Center Regional Study

Asma Deeb  1 , Saif Al Yaarubi  2 , Bassam Bin Abbas  3 , Jamal Al Jubeh  4 , Deepti Chaturvedi  5 , Noura Al Hassani  6 , Angham Mutair  7 , Neamat Al Masri  1 , Yazan Al Sanad  1 , Azza Al Shidhani  2 , Noha Samir Mahmoud  8 , Abdullah Alherbish  8 , Martin O Savage  9
Affiliations

Patients' Perception of the Use of the EasyPod™ Growth Hormone Injector Device and Impact on Injection Adherence: A Multi-Center Regional Study

Asma Deeb et al. Front Pediatr. .

Abstract

Objective: This study aimed to assess patient perceptions of the use of the EasyPod™ growth hormone delivery device and its association with compliance.

Methods: This cross-sectional, multicenter study was conducted in six centers from three countries (United Arab Emirates, Oman, and Saudi Arabia,) between March 2020 and June 2020. Children and adolescents aged 3-18 years, diagnosed with growth disorders and receiving rhGH through the EasyPod™ device were enrolled. Patients and caregivers were given a pre-set questionnaire that evaluated patient satisfaction, preference for technical and personalized features, and device drawbacks. The results were analyzed using independent measures of analysis of variance to evaluate the association of higher satisfaction with device features and better compliance.

Results: A total of 186 patients were enrolled in the study. Of these, 45.7% had GH deficiency. The mean age (±SD) of patients was 11.8 (±2.76) years; 117 (62.90%) were males. Average compliance was 87%. One hundred patients (53.76%) had injection compliance of ≥90%. Amongst these patients, 74%, 68%, and 77% top-scored (5/5) the technical features of hidden needle, skin sensor, and pre-set dosing, respectively, compared to top scores by 39%, 34%, and 51% patients in the <90% compliance group (p-value <0.05). Similarly, a statistically significant difference was observed between the groups (p-value <0.05) in the perception of the usefulness of the tracking features such as display of history of injected doses (78% vs. 47.7%), a reminder for medicine remaining (46% vs. 23.3%) and battery power indicator (48% vs. 20.9%). Personal screen messages were associated with higher compliance while the requirement to keep the device in the fridge was reported as the most inconvenient feature by 56% of patients in the higher compliance group as against 39.5% in the lower compliance group (p-value <0.05). There was no statistically significant difference in the intensity of pain reported in the two compliance groups.

Conclusion: Our study showed that there is a statistically significant association between better perception of device features and higher compliance.

Keywords: EasyPod™; compliance; growth hormone deficiency; injector device features; recombinant human growth hormone.

PubMed Disclaimer

Conflict of interest statement

This publication received funding from Merck Serono Middle East FZ-LTD. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication. This publication is done via an unrestricted medical writing grant by Merck Serono Middle East FZ-LTD, an affiliate of Merck KGaA, Darmstadt, Germany. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Grimberg A, DiVall SA, Polychronakos C, Allen DB, Cohen LE, Quintos JB, et al. . Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. Horm Res Paediatr. (2016) 86:361–97. 10.1159/000452150 - DOI - PubMed
    1. Maggio MC, Vergara B, Porcelli P, Corsello G. Improvement of treatment adherence with growth hormone by EasyPod® device: experience of an Italian centre. Ital J Pediatr. (2018) 44:113. 10.1186/s13052-018-0548-z - DOI - PMC - PubMed
    1. Lee PA, Germak J, Gut R, Khutoryansky N, Ross J. Identification of factors associated with good response to growth hormone therapy in children with short stature: results from the ANSWER Program®. Int J Pediatr Endocrinol. (2011) 2011:6. 10.1186/1687-9856-2011-6 - DOI - PMC - PubMed
    1. Pfäffle . R. Hormone replacement therapy in children: the use of growth hormone and IGF-I. R Best Pract Res Clin Endocrinol Metab. (2015) 29:339–52. 10.1016/j.beem.2015.04.009 - DOI - PubMed
    1. Collett-Solberg PF, Ambler G, Backeljauw PF, Bidlingmaier M, Biller BMK, Boguszewski MCS, et al. . Diagnosis, genetics, and therapy of short stature in children: a Growth Hormone Research Society International Perspective. Horm Res Paediatr. (2019) 92:1–14. 10.1159/000502231 - DOI - PMC - PubMed

LinkOut - more resources